Skip to content
value.today

Clarient, Inc.

Formerly ChromaVision Medical Systems, Inc., MicroVision Medical Systems, Inc.

Total raised
$29 M
1 round on record
Latest round
$29 M
Mar 2009
First round on record
Mar 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Clarient, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2009$11 MIssued in a merger or acquisition$10 to $50 million

Clarient, Inc.: Private sale, Dec 2009

Investors in this round

56 investors had bought by the notice of Dec 31, 2009: 43 accredited, 13 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $19 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Daly · Executive Officer
  • Michael J. Pellini · Executive Officer
  • Michael R. Rodriguez · Executive Officer
  • Ron J. Collette · Executive Officer
  • Ronald A. Andrews · Executive Officer, Director
  • Andrew H. Adams · Director
  • Ann H. Lamont · Director
  • Dennis M., Jr. Smith · Director
  • Frank P., Jr. Slattery · Director
  • Gregory D. Waller · Director
  • James A. Datin · Director
  • Peter J. Boni · Director
  • Stephen T. Zarrilli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael R. Rodriguez, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 31, 2009. Read the notice at the SEC.

equity, optionsSEC
Mar 2009$29 MNo. 1$10 to $50 million

Clarient, Inc.: Raise no. 1, Mar 2009

Investors in this round

1 investor had bought by the notice of Apr 8, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $40 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
$1,100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • David J. Daly · Executive Officer
  • Michael J. Pellini · Executive Officer
  • Raymond J. Land · Executive Officer
  • Ronald A. Andrews · Executive Officer, Director
  • Andrew Adams · Director
  • Ann H. Lamont · Director
  • Dennis M., Jr. Smith · Director
  • Frank P., Jr. Slattery · Director
  • Gregory D. Waller · Director
  • James A. Datin · Director
  • Peter J. Boni · Director
  • Stephen T. Zarrilli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • RBC Capital Markets Corporation (CRD 31194) · broker-dealer RBC Capital Markets Corporation (CRD 31194) · New York, NySold in no state named

Signed by Raymond J. Land, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 8, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Clarient, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Dec 2009).

    SEC Form D (revenue range) · Dec 2009

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2009

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Clarient, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Clarient, Inc.
NameRoleNamed in
David J. DalyExecutive officerDec 2009
Michael J. PelliniExecutive officerDec 2009
Michael R. RodriguezExecutive officerDec 2009
Ron J. ColletteExecutive officerDec 2009
Ronald A. AndrewsExecutive officerDec 2009
Raymond J. LandExecutive officerApr 2009
Andrew H. AdamsDirectorDec 2009
Ann H. LamontDirectorDec 2009
Dennis M., Jr. SmithDirectorDec 2009
Frank P., Jr. SlatteryDirectorDec 2009
Gregory D. WallerDirectorDec 2009
James A. DatinDirectorDec 2009
Peter J. BoniDirectorDec 2009
Ronald A. AndrewsDirectorDec 2009
Stephen T. ZarrilliDirectorDec 2009
Andrew AdamsDirectorApr 2009